453 results about "Pulmonary artery" patented technology

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

Interatrial shunts having incorporated physiologic sensors are provided for monitoring and treating cardiovascular syndromes, including heart failure and pulmonary hypertension, in which the one or more sensors are affixed to the shunt to measure a physiologic parameter within the interatrial shunt. The one or more sensors may be directly affixed to or within a lumenal surface of the shunt or may be disposed on a support structure in a spaced relation to the shunt lumen, the one or more sensors disposed at locations subject to little or no pannus formation or cardiac wall motion artifact.

The invention discloses a method for noninvasive diagnosis of pulmonary arterial hypertension and a related device, and relates to the technical field of artery detection.The method comprises the steps that an echocardiogram result and right heart catheter pulmonary artery pressure data of a suspected pulmonary artery patient are obtained; the echocardiogram result is a tricuspid regurgitation spectrum; grading the quality of the tricuspid regurgitation spectrum based on a TR spectrum quality grading standard according to the regurgitation spectrum missing degree of the tricuspid regurgitation spectrum; according to the echocardiogram result and the right heart duct pulmonary artery pressure data, on the basis of the quality grading result of the tricuspid regurgitation spectrum, a personalized pulmonary artery hypertension diagnosis model suitable for different patients is constructed; according to the pulmonary arterial hypertension diagnosis model, on the basis of the echocardiogram result of the target pulmonary arterial patient, a pulmonary arterial hypertension diagnosis result of the target pulmonary arterial patient is obtained, and personalized accurate diagnosis can be carried out on different pulmonary arterial hypertension patients under the noninvasive condition.

The invention provides a pulmonary artery hemodynamic parameter prediction method and system, and relates to the technical field of medical image processing. The method comprises the following steps: acquiring an original CXR image of a patient; preprocessing the original CXR image to obtain a target CXR image; constructing an image segmentation model based on a U-Net segmentation network; inputting the target CXR image into the image segmentation model for segmentation, and outputting a right lower pulmonary artery ROI region image; the method comprises the steps that a pulmonary artery hemodynamic parameter prediction model is constructed, and the pulmonary artery hemodynamic parameter prediction model comprises a Swin-Transform branch and a CNN branch; and inputting the target CXR image to the Swindow-Transform branch, inputting the right lower pulmonary artery ROI region image to the CNN branch, and outputting a prediction result of the pulmonary artery hemodynamic parameters.

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

A clinical decision support system and method for patients with pulmonary arterial hypertension is disclosed herein. The system may comprise a processor to process instructions to execute one or more pulmonary arterial hypertension risk algorithms configured to generate a risk score value associated with a patient surviving within a given time period. The system may comprise a means for input and output, wherein input variable data may be received and a set of risk score values may be displayed. A method for operating the clinical decision support system is also disclosed.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a pulmonary artery segmentation method, system and device based on RNN, and a medium, relates to pulmonary artery segmentation by using an artificial intelligence technology, and aims to solve the technical problem that the pulmonary artery segmentation accuracy is affected by incomplete label data due to difficult labeling of peripheral branches of a pulmonary artery in the prior art. The sample comprises a labeled lung CT sample image and an unlabeled lung CT sample image; the pulmonary artery segmentation model comprises a U-Net network and two Mama networks with selective state spaces, an nmODE module is introduced in an intermediate high-dimensional representation stage of the U-Net network, one Mama network is used for constructing a scoring function for predicting the probability that each voxel is a foreground, and the other Mama network is used for constructing a scoring function for predicting the probability that each voxel is a foreground; the other Mamba network is used for constructing a labeling tendency function for estimating the possibility that the voxel is manually labeled as a foreground; an image is input into the U-Net network, original features are extracted after a down-sampling stage, then the original features are converted into feature representations after being dynamically mapped by the nmODE module, the original features are respectively input into the two Mamba networks after an up-sampling stage, and a real structure and an annotation state are output.

The invention discloses a risk assessment method, system and equipment for idiopathic pulmonary arterial hypertension, and belongs to the field of pulmonary arterial hypertension. According to the method, SNP data containing genotypes and effect values, protein marker expression quantity, metabonomics and clinical data are obtained, the SNP effect values are corrected based on linkage imbalance reference information, and PRS is calculated in combination with the genotypes; constructing a protein expression score by utilizing the site effect value and the expression quantity of the pQTL, and fusing the protein expression score with the PRS to form a target PRS; carrying out dimensionality reduction on metabolome data by adopting sparse coding, extracting sparse coefficients of IPAH related metabolic pathways, and converting the sparse coefficients into metabolic pathway scores; converting the clinical indexes into clinical risk scores; based on the clinical parameter distribution target PRS, the metabolic pathway score and the weight coefficient of the clinical risk score, calculating a risk assessment value; and finally, matching the evaluation value with a preset risk threshold value, and outputting a risk evaluation level. And the IPAH risk assessment accuracy of common people is improved.

The utility model relates to the technical field of medical instruments, in particular to a pulmonary artery multistage conveying catheter. The pulmonary artery multistage conveying catheter comprises an outer sheath tube, a middle catheter and a working catheter, a first balloon is arranged on the outer wall of one end of the outer sheath tube, a first airflow cavity channel penetrating out of the side wall of the other end of the outer sheath tube is formed in the outer sheath tube, one end of the first airflow cavity channel is communicated with the first balloon, and the other end of the first airflow cavity channel is communicated with the working catheter. The middle catheter penetrates through one end of the outer sheath tube, a second balloon is arranged on the outer wall of one end of the middle catheter, a second airflow cavity channel penetrating out of the side wall of the other end of the middle catheter is formed in the middle catheter, one end of the second airflow cavity channel is communicated with the second balloon, and the working catheter penetrates through one end of the middle catheter. The utility model has the advantages of simple and reasonable structural design, can be specially used for the vast majority of operations of pulmonary vessels, greatly saves the operation time, and reduces the consumable cost of patients.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

According to the technical scheme, the invention discloses a non-invasive pulmonary arterial pressure and capillary wedge pressure continuous estimation device which comprises a three-axis inertial sensing module, an acoustic sensing module, an electrocardio electrode module, a feature extraction module, a calibration and estimation module and an edge calculation module. Single three-axis inertial sensing and acoustic signal fusion are utilized, and the PAP and the PCWP are continuously estimated in a non-intrusive mode through a calibration regression / deep learning algorithm. According to the invention, single inertia and acoustics are innovatively taken as a collection core, and a calibration-estimation closed loop is supplemented, so that the device has the advantages of long-term continuous monitoring and real-time output of hemodynamic parameters in low-trauma, wearable and mobile environments.

The invention discloses an intermittent occlusion balloon catheter system for treating heart failure. The system comprises a five-cavity double-balloon catheter, the five-cavity double-balloon catheter comprises a cavity tube body, a first balloon arranged in a pulmonary artery and a second balloon arranged in a superior vena cava, and the first balloon and the second balloon are both fixed to the surface of the cavity tube body; a round head is arranged at the far end of the cavity tube body, and the diameter of the round head is not larger than the outer diameter of the catheter. The near end is connected with the extension tube assembly through an injection molding head; the cavity tube body is provided with five cavity channels which are respectively communicated with the first balloon extension tube, the second balloon extension tube, the thermistor extension tube, the far-end extension tube and the near-end extension tube; the injection pump is driven by the stepping motor, and the controller adjusts the advancing and retreating motion period of the stepping motor, so that the injection pump is controlled to charge and discharge liquid to the second balloon. By intermittently blocking the superior vena cava, the heart filling pressure is reduced, and therefore heart hyperemia and volume overload are prevented.

The embodiment of the invention provides a pulmonary artery image anomaly classification method and device, equipment and a medium. The pulmonary artery image anomaly classification method comprises the steps that a target CT image and a target ultrasonic image of a pulmonary artery are acquired; respectively coding the target CT image and the target ultrasonic image, and respectively extracting first global and local features of the target CT image and second global and local features of the target ultrasonic image after coding; performing weighted fusion on the first global and local features and the second global and local features through a preset multi-head attention mechanism to obtain multi-modal fusion features; performing decoding processing on the multi-modal fusion features, and performing reconstruction after decoding processing to obtain a target fusion image of the pulmonary artery; and performing anomaly classification based on the target fusion image to obtain an anomaly classification result of the pulmonary artery, thereby improving the accuracy of anomaly classification of the pulmonary artery image.

The utility model relates to the technical field of medical instruments, in particular to a pulmonary artery wedge pressure balloon. The pulmonary artery wedge pressure balloon comprises a catheter and a balloon body, one end of the catheter is provided with an inclined and elastic bent section, the balloon body is arranged on the outer wall of the end of the bent section, an airflow cavity channel communicated with an inner cavity of the balloon body is formed in the catheter, and the airflow cavity channel penetrates out of the side wall of the other end of the catheter. The pulmonary artery pressure detector has the advantages that the structural design is simple and reasonable, the use cost is low, and the pulmonary vessel pressure information of a pulmonary artery hypertension patient can be effectively detected, so that medical staff can judge the drug effect of administration according to the information or accurately evaluate the interventional operation of the patient.

The invention discloses an application of beta-alanine in preparation of a medicine for treating pulmonary arterial hypertension. In-vivo and in-vitro pharmacological experiments prove that beta-alanine can inhibit lactic acid-mediated histone milk acylation modification and hypoxia-induced phenotypic transformation of PASMCs (Polyaspartic Sulfonate Molecules); the hemodynamics and pulmonary artery vascular remodeling of the PAH mouse are improved. The beta-alanine can inhibit phenotypic transformation of PASMCs and reverse pulmonary artery vascular remodeling which is a key pathological change in the pulmonary hypertension generation process, has huge potential in treatment of pulmonary hypertension, and has good application prospects and high clinical application value.

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

The invention discloses an ultrasonic pulmonary artery segmentation method, system and equipment based on anatomical perception and a medium, belongs to pulmonary artery segmentation in an artificial intelligence technology, and aims to solve the technical problems of low accuracy and poor segmentation integrity of pulmonary artery segmentation. Comprising the steps of sample image acquisition, classification network fine adjustment and feature extraction, initial response diagram generation, pseudo label generation, segmentation network construction and first training, dynamic anatomy constraint iteration training and pulmonary artery real-time segmentation. When a pseudo label is generated, constructing an anatomical perception pseudo label generation module, inputting the initial response graph into the anatomical perception pseudo label generation module, and outputting an initial pseudo label by the anatomical perception pseudo label generation module; and during iterative training, constructing a differentiable anatomical constraint generator, and performing iterative training on the segmentation network by using the differentiable anatomical constraint generator. A rough and sparse initial response graph is converted into a complete, continuous and reasonably dissected initial pseudo-tag through a pseudo-tag generation module for dissecting perception.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum, and a drug-eluting biodegradable material that biodegrades over time to release a drug that limits tissue overgrowth. The inventive device also may include a biodegradable material that biodegrades to offset flow changes caused by tissue overgrowth. The inventive device may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits.

The invention provides a self-adaptive control method and device for a double-ventricle auxiliary system. The method comprises the steps that target aortic pressure detected by a first pressure sensor, target left ventricular end diastolic pressure detected by a second pressure sensor, target right atrial pressure detected by a third pressure sensor and target pulmonary artery pressure detected by a fourth pressure sensor are obtained; and determining a strategy for adjusting the left ventricular assist device or the right ventricular assist device according to the target left ventricular end diastolic pressure, the target right ventricular pressure and the target pulmonary arterial pressure when the peripheral perfusion of the target user is insufficient or the lung is over-perfused. The pressure sensors are arranged to detect the pressure of the inlets and the outlets of the left ventricular assist device and the right ventricular assist device, whether adverse events such as peripheral insufficiency or pulmonary hyperperfusion occur to a user or not is judged according to the detected pressure, and then the adverse events are relieved or even solved by adjusting the rotating speeds of the left ventricular assist device and the right ventricular assist device. And the safety of the user is greatly improved.

The invention provides a close-range valve-pump integrated ventricular auxiliary circulating pump device, and relates to the technical field of heart blood pumps, the close-range valve-pump integrated ventricular auxiliary circulating pump device comprises a ventricular auxiliary circulating pump device, the ventricular auxiliary circulating pump device is connected in series with a heart artery tube, and the ventricular auxiliary circulating pump device is arranged in a heart chamber and below an aortic valve or a pulmonary artery valve; the ventricular auxiliary circulating pump device comprises an axial flow channel and a power part located in the axial flow channel. The upper end of the axial flow channel is provided with a radially outward turnup part, the turnup part faces the lower surface of the aortic valve or the pulmonary valve and is sewn at the aortic root or the pulmonary artery root, the turnup part serves as a mounting plane, and the power part is provided with an impeller rotating in the axial direction of the axial flow channel. The plane of the outlet of the impeller and the plane where the flanging part is located are the same plane, and direct adjacent maximum pressure of the ventricular auxiliary circulating pump device is provided for the aortic valve or the pulmonary valve.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: •a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and•a therapeutically effective amount of a dimeric fusion protein comprising: •the extracellular domain of the activin type 2A (ACTR IIA) or the activin type 2B receptor (ACTR IIB); and the Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is Seralutinib or a pharmaceutically acceptable salt thereof and the fusion protein is Sotatercept.

In some aspects, the present disclosure relates to compositions and methods comprising ActRII polypeptides for treating, preventing, or reducing the rate of progression and / or severity of postcapillary pulmonary hypertension (PcPH), particularly for treating, preventing, or reducing the rate of progression and / or severity of one or more PcPH-related complications. ActRII polypeptides may include polypeptides including any naturally occurring polypeptide of an ActRII family member, and any variant thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain useful activity.

The invention discloses a blood leakage rate measuring device and method and a clinical actual blood flow obtaining method. The blood leakage rate measuring device comprises a right heart simulator filled with liquid and a pulmonary artery simulator, a second pressure sensor and a first pressure sensor are installed at the bottom in the right heart simulator and the pulmonary artery simulator, the right heart simulator is communicated with the pulmonary artery simulator through a first pipeline and a second pipeline, and an auxiliary pump is installed on the first pipeline. The right heart auxiliary catheter penetrates through the right heart simulator, the valve assembly is arranged in liquid in the right heart simulator, the end cap is arranged in liquid in the pulmonary artery simulator, a second flow sensor is installed on the outer wall of the short tube part between the right heart simulator and the pulmonary artery simulator, and a first flow sensor is installed on the outer wall of the long tube part close to the extracorporeal membrane type cavity. According to the clinical actual blood flow obtaining method, the actual blood flow of the right heart auxiliary catheter can be accurately obtained through the obtained blood leakage rate.

A right ventricular assist device (hereinafter, “RVAD”) for placement inside a mammalian subject includes a tube having an inlet configured to be positioned in the mammalian subject when the tube is in a proper position within a heart and an outlet configured to be located in a pulmonary artery when the tube is in the proper position. The RVAD also includes a plurality of sensors having measurement locations along the tube to measure a plurality of pressures of blood exterior to the tube at the measurement locations and a controller in communication with the pump and the plurality of sensors that convey the plurality of pressures to the controller with the controller being configured to instruct the pump to pump blood through the tube depending on at least one of the plurality of pressures.

A tricuspid regurgitation treatment tool to be inserted into the pulmonary artery is proposed. The tricuspid regurgitation treatment tool to be inserted into the pulmonary artery is used to verify whether the right ventricular dysfunction may occur when treating the tricuspid regurgitation by surgeries or other permanent treatments. A test insertion of the tricuspid regurgitation treatment tool to be inserted into the pulmonary artery is made to pass obliquely through the tricuspid valve of a patient, and after a certain time has elapsed, the tool is removed. The tricuspid regurgitation treatment tool to be inserted into the pulmonary artery includes: a blocking part blocking the tricuspid valve; and an insertion tube provided with a guidewire-guiding lumen formed therein to be movable along the guidewire.

The invention discloses a cryoablation catheter system for pulmonary artery stent internal restenosis, and belongs to the field of medical instruments, the cryoablation catheter system comprises a catheter main body arranged on a guide wire, the catheter main body is provided with a treatment assembly, the treatment assembly is located at the far end of the catheter main body, the catheter main body is provided with a control handle, and the control handle is located at the far end of the catheter main body. The control handle is located at the near end of the catheter body, and the treatment assembly comprises a near-end balloon, a far-end balloon and a freezing balloon. When the near-end balloon and the far-end balloon are simultaneously full, a closed treatment cabin isolated from near-end blood flow and far-end blood flow can be formed in a blood vessel of a target treatment section, the freezing balloon is located in the treatment cabin, the closed treatment cabin thoroughly eliminates the blood flow hot pool effect, cold is prevented from being taken away by the blood flow, and the treatment effect is improved. Freezing energy is intensively acted on a diseased region, so that the ablation efficiency and accuracy are improved; meanwhile, thrombus, tissue debris and whole body blood flow which fall off in the treatment process are isolated, the risk of far-end embolism is reduced from the source, and damage to the blood vessel wall is avoided.

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).